evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,320 questions · 4,561 findings · 388 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,138 · 25%GRADE not reported 886 · 19.4%Very low 1,014 · 22.2%Low 849 · 18.6%Moderate 543 · 11.9%High 131 · 2.9%

Perampanel add‐on vs placebo

Withdrawals due to adverse events · people (aged 12 years and over) with drug‐resistant focal epilepsy

Perampanel add‐on may leads to higher treatment withdrawal due to adverse effects compared with placebo (low certainty).

1 finding from 1 review

Perampanel add‐on vs placebo

Proportion of participants who experienced ≥ 1 adverse effect · people (aged 12 years and over) with drug‐resistant focal epilepsy

Perampanel add‐on leads to higher proportion of participants who experienced ≥ 1 adverse effect compared with placebo (high certainty).

1 finding from 1 review

Perampanel add‐on vs placebo

Proportion of participants who experienced ataxia · people (aged 12 years and over) with drug‐resistant focal epilepsy

Perampanel add‐on may leads to higher proportion of participants who experienced ataxia compared with placebo (low certainty).

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Survival · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype
1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Quality of life: total score · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

FEV1 % predicted: relative change from baseline · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

FEV1 % predicted: absolute change from baseline · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype
1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Adverse events ‐ treatment emergent · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor showed no clear difference in adverse events: number of participants with treatment‐emergent… compared with control (ivacaftor alone or tezacaftor plus ivacaftor) (moderate certainty).

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Time to first pulmonary exacerbation · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

The review found no eligible studies for this question.

1 finding from 1 review